Prophylactic treatment with the c-Abl inhibitor, neurotinib, diminishes neuronal damage and the convulsive state in pilocarpine-induced mice

oleh: América Chandía-Cristi, Daniela A. Gutiérrez, Andrés E. Dulcey, Marcelo Lara, Lina Vargas, Yi-Han Lin, Pablo Jimenez-Muñoz, Gabriela Larenas, Xin Xu, Amy Wang, Ashley Owens, Christopher Dextras, YuChi Chen, Claudio Pinto, Tamara Marín, Hugo Almarza-Salazar, Keryma Acevedo, Gonzalo I. Cancino, Xin Hu, Patricio Rojas, Marc Ferrer, Noel Southall, Mark J. Henderson, Silvana Zanlungo, Juan J. Marugan, Alejandra Álvarez R

Format: Article
Diterbitkan: Elsevier 2024-05-01

Deskripsi

Summary: The molecular mechanisms underlying seizure generation remain elusive, yet they are crucial for developing effective treatments for epilepsy. The current study shows that inhibiting c-Abl tyrosine kinase prevents apoptosis, reduces dendritic spine loss, and maintains N-methyl-d-aspartate (NMDA) receptor subunit 2B (NR2B) phosphorylated in in vitro models of excitotoxicity. Pilocarpine-induced status epilepticus (SE) in mice promotes c-Abl phosphorylation, and disrupting c-Abl activity leads to fewer seizures, increases latency toward SE, and improved animal survival. Currently, clinically used c-Abl inhibitors are non-selective and have poor brain penetration. The allosteric c-Abl inhibitor, neurotinib, used here has favorable potency, selectivity, pharmacokinetics, and vastly improved brain penetration. Neurotinib-administered mice have fewer seizures and improved survival following pilocarpine-SE induction. Our findings reveal c-Abl kinase activation as a key factor in ictogenesis and highlight the impact of its inhibition in preventing the insurgence of epileptic-like seizures in rodents and humans.